Dalpiciclib
- Generic Name
- Dalpiciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O2
- CAS Number
- 1637781-04-4
- Unique Ingredient Identifier
- 5ZHA5P4PFX
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 265
- Registration Number
- NCT05949541
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 30
- Registration Number
- NCT05806671
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 145
- Registration Number
- NCT05759572
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05759546
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT05638594
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- Drug: PIK3CA inhibitorDrug: AKT inhibitorDrug: SHR-A1811Drug: CarrelizumabDrug: SHR-1167Drug: FamitinibDrug: SorafenibDrug: EverolimusDrug: FluzoparibDrug: Aromatase Inhibitors or FulvestrantDrug: TPCDrug: SHR-A1921Drug: SHR-6209Drug: DalpiciclibDrug: ApatinibDrug: SHR-A2009Drug: SHR-A2102Drug: GoserelinDrug: bevacizumab
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05586841
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 420
- Registration Number
- NCT05578053
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 126
- Registration Number
- NCT05577923
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath